.png){kind=icon}
.png){kind=icon}
Return
GDPPH1 induces cell cycle arrest by downregulation of CDK4/Cyclin D1 via the m6A-METTL14-YTHDF2 axis, attenuating glioblastoma progression
.png){kind=icon}
OA
AI
S
R
J
R
X
L
Q
Z
S
J
X
Z
K
S
Y
L
Z
Z
W
Y
Y
Z
齐
DOI：10.1038/s41419-026-09036-x.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Glioblastoma (GBM) is the most prevalent and aggressive primary brain tumor in adults, with current therapies failing to achieve significant clinical advancements. GDPPH1, a natural compound derived from Garcinia mangostana L., is known for its antioxidant properties; however, its anticancer effects and underlying mechanisms remain insufficiently understood. In this study, we demonstrate that GDPPH1 significantly inhibits GBM cell proliferation in a concentration-dependent manner by downregulating CDK4 and Cyclin D1 expression, inducing cell cycle arrest at G1/S checkpoint, and promoting apoptosis. Mechanistically, GDPPH1 reduces the m6A methylation of CDK4 and CCND1 through METTL14-YTHDF2-mediated transcript decay, resulting in decreased CDK4/CCND1 expression and subsequent decreased RB phosphorylation levels. Further studies revealed that m6A-METTL14-YTHDF2 axis is responsible for GDPPH1-induced downregulation of CDK4 and Cyclin D1. Additionally, the in vivo anti-GBM efficacy of GDPPH1 was confirmed using both xenograft and orthotopic intracranial mouse models. Collectively, these findings provide robust evidence supporting GDPPH1 as a promising therapeutic candidate for GBM and offer novel insights into the role of m6A RNA methylation in cell cycle regulation.
Journal
C
IF:
9.6
Papers:
790
Citations:
0
View more organizations